Abstract. The aims of this retrospective survey were to determine the epidemiologic distribution of hepatitis B virus (HBV) genotypes and analyze the genotype-related clinical differences among Japanese patients with chronic HBV infection. The 158 surveyed patients with chronic HBV infection lived in Fukuoka and Okinawa were serially tested for serum alanine aminotransferase (ALT) and hepatitis B e antigen (HBeAg). Follow-up was for a period of 10.8 ± 6.4 years (mean ± SD). The HBV genotypes were determined in sera by an enzyme-linked immunosorbent assay and detection of HBV DNA in serum was done by the transcription-mediated amplification−hybridization protection assay. Genotypes B and C were found in 58 (36.7%) and 100 (63.3%) of the patients, respectively. Genotype B was predominant in Okinawa (B ‫ס‬ 86.9%, C ‫ס‬ 13.1%), whereas genotype C was predominant in Fukuoka (B ‫ס‬ 5.2%, C ‫ס‬ 94.8%). The HBeAg positivity and ALT abnormality rates at the start of the observation period were significantly higher in patients with genotype C (66.0% and 84.0%) than in patients with genotype B (34.5% and 22.4%) (P < 0.05, respectively). The annual rate of spontaneous HBeAg disappearance in patients with genotype B was much higher than in patients with genotype C (8.38% versus 2.34%, respectively). Patients with genotype C who were continuously HBeAg negative from entry had a significantly higher ALT abnormality (58.8%) than those with genotype B (19.2%) (P < 0.05). Interestingly, patients with genotype C who became HBeAg negative after treatment with interferon had a high ALT abnormality (58.8%). All patients with an ALT abnormality were positive for HBV DNA in their serum. These findings indicate that patients with HBV genotype C have more severe liver deterioration because of the delay of HBeAg disappearance and continued HBV replication after HBeAg disappearance.
INTRODUCTION
Hepatitis B virus (HBV) infection is a global public health problem. It is estimated that there are more than 300 million HBV carriers in the world, of whom one million will die annually from HBV-related liver disease. 1 Seventy-five percent of patients with chronic HBV infection are Asian. 2 Our laboratory previously reported that the Yaeyama district of Okinawa, Japan was highly endemic for HBV infection, [3] [4] [5] and that the number of newly infected residents has decreased there, as documented in our long-term study. 6, 7 The HBV surface antigen (HBsAg) subtypes show distinct geographic distributions, 8 and previous reports strongly suggest HBV transmission within families or by close contact with members. 3, 9 We have also demonstrated that the rates and ages of seroconversion from hepatitis B e antigen (HBeAg) to antibody to HBeAg (anti-HBe) were higher and younger in people with HBsAg subtype adw than in those with adr, suggesting that the HBsAg subtype may be closely associated with the HBeAg/anti-HBe status. 10 The serologic heterogeneity of the HBV genome has been established, 11 and seven genotypes, A to G, have been classified based on comparison of complete HBV genomes. 12, 13 These genotypes have a distinct geographic distribution. Genotype A is prevalent in northern Europe, North and South America, and Africa. Genotypes B and C are found in eastern and Southeast Asia. Genotype D has spread worldwide, but predominates in the Mediterranean area. Genotype E is found mainly in the western part of Sub-Saharan Africa. Genotype F is found among the indigenous peoples of Central and South America. 14, 15 Recently, a new genotype G was found in samples from the United States and France. 16 This HBV genome variation could explain the geographic differences in the natural course of chronic HBV infection.
However, the clinical significance of HBV genotypes has not been well studied in Japan. With improved knowledge of the relationship between the natural course of chronic HBV infection and the genotype, clinicians will be able to focus treatment strategies and research on specific patient populations. To clarify the different clinical outcomes of HBV infection by HBV genotype, we investigated the epidemiologic distribution of HBV genotypes and retrospectively analyzed the genotype-related differences involved in the pathogenicity of HBV among Japanese patients with chronic HBV infection.
MATERIALS AND METHODS

Patients.
One hundred fifty-eight Japanese patients with chronic HBV infection, 97 followed as outpatients at the Department of General Medicine, Kyushu University Hospital (Fukuoka Prefecture) and 61 who have had part in our HBV survey of the Yaeyama District of Okinawa Prefecture since 1978, 4, 7, 17 were retrospectively studied. The HBV genotypes were determined in sera by an enzyme-linked immunosorbent assay (ELISA) in December 2000. This and our previously reported prospective HBV study 17 of Okinawa have continued since 1978. Blood samples were collected from residents reporting for free health examinations and who were available for follow-up. The following criteria were fulfilled by all patients: 1) positive for HBsAg for at least six months, to establish chronic HBV infection; and 2) exclusion of other concomitant causes of liver disease (hepatitis C and alcohol consumption more than 80 grams/day) and relatively rare liver disease (autoimmune hepatitis and metabolic liver disease). The outpatients studied at our department also fulfilled these criteria and have been followed-up since 1988. This group included patients with and without abnormal liver function test results. The protocol of the study was reviewed and approved by the Ethic Committee of Kyushu University, and informed consent to participate in the study was obtained from all adult participants and from the patients or legal guardians of minors. Fukuoka Prefecture is located in the north part of Kyushu Island, the most southern of the main islands of Japan. Okinawa is located in the subtropical zone approximately 1,000 km south of the main islands of Japan, which lie in the temperate zone. The Yaeyama District, with nine inhabited islands, is southwest of Okinawa, near Taiwan ( Figure 1 ).
All patients were selected based on the availability of four or more serum samples over the observation period of at least two years (mean ± SD ‫ס‬ 10.8 ± 6.4 years) from 1978 to 2000. They included 88 (55.7%) males and 70 (44.3%) females 5-74 years old (mean ± SD ‫ס‬ 35.9 ± 15.9 years). All patients were negative for antibodies to hepatitis C virus and human immunodeficiency virus. All causes of chronic liver disease other than HBV were excluded by appropriate clinical and laboratory evaluations. Forty nine (31.0%) patients received treatment with interferon (IFN)-␣ (subcutaneously at a dose of six million unit (MU) a day for four weeks) during the observation period, while none of the remaining 109 (69.0%) patients had ever received IFN, corticosteroid-withdrawal treatment, or other antiviral treatment. All patients had serially undergone testing for HBeAg and alanine aminotransferase (ALT) levels at least every four months during the observation period. To analyze the genotype-related differences, all patients were divided into four groups according to their HBeAg status during the observation period (Group I, continuously HBeAg positive; Group II, converted from HBeAg-positive to HBeAg-negative without IFN treatment; Group III, converted from HBeAg-positive to HBeAb-negative after IFN treatment; Group IV, continuously HBeAg negative). Abnormal ALT was defined as an ALT level greater than 35 IU/L for more than half of the patient's observation period. Interferon was a standard treatment of patients with chronic HBV infection before lamivudine became available. Medical insurance in Japan pays for IFN treatment of such patients on the condition that patients are positive for HBeAg. Therefore, none of the group IV patients, who were negative for HBeAg on enrollment, could receive IFN treatment.
Serologic assays. All serum samples were separated and stored at -20°C until testing for HBsAg, HBeAg, HBsAg subtype, HBV genotype, and HBV DNA. The HBsAg subtype was determined by enzyme immunoassay using monoclonal antibodies (HBsAg Subtype EIA; Institute of Immunology, Tokyo, Japan). The presence of HBeAg was determined by radioimmunoassay (RIA) (HBeAg RIA; Abbott Laboratories, Abbott Park, IL).
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HBV genotyping by ELISA. An ELISA was developed for serologic determination of the six HBV genotypes designated A, B, C, D, E, and F. Monoclonal antibodies were raised against genotype-specific epitopes in the preS2-region product of HBV, and labeled with horseradish peroxidase. The HBsAg in sera was captured by immobilized antibodies against the common determinant, and evaluated for reactivity with genotype-specific monoclonal antibodies labeled with the enzyme. This ELISA would be useful for large-scale surveys because it allows serologic detection of HBV genotypes without sequencing nucleotides. Quantitative detection of HBV DNA. Detection of serum HBV DNA was done by a transcription-mediated amplification−hybridization protection assay (TMA-HPA) (DNA probe Chugai-HBV; Chugai, Tokyo, Japan) with a lower detection limit of approximately 500 viral genome copies/mL (3.7 log genome equivalents/mL). We checked HBV DNA viremia in all patients by this assay twice (approximately six months before and at the same time as the genotype at the end of the observation period was determined). Because the sensitivity of the TMA-PHA method is 100-fold that of the branched DNA probe assay, serum HBV DNA detection by the TMA-PHA method is more useful in HBeAg-negative patients than in HBeAg-positive patients, suggesting that the method would be useful in estimating the relationship between viral replication and disease prognosis in patients with chronic HBV infection.
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Statistical analysis. Continuous data were expressed as means ± standard deviations. The unpaired t-test and the Mann-Whitney U test were used to compare the means of samples between the two groups. The chi-square test or Fisher's exact test was used for categorical variables for comparisons between the two groups. The annual HBeAg disappearance rate was estimated by person-year method. Cumulative probabilities of HBeAg disappearance between two groups were done with the Kaplan-Meier life table (actuarial) method and compared by the log rank test. A P value of 0.05 or less was considered statistically significant. Patient characteristics at start of the observation period by HBV genotype. Table 1 shows the baseline clinical data of all 158 patients with chronic HBV infection. No significant difference in male:female ratio or mean age was observed between the two groups when classified by HBV genotype. The distribution of HBsAg subtypes was 64 adr (40.5%), 34 adw (21.5%), 20 adwr (12.7%), 10 adyr (6.3%), and 30 (19.0%) subtype not determined. Subtype adw was found only in the patient group with genotype B, while subtype adr was found only in the patient group with genotype C. Subtypes adwr and adyr were found significantly more often in patients with genotype C than in patients with genotype B (P ‫ס‬ 0.0007 and P ‫ס‬ 0.0140, respectively). Conversely, subtype not determined was found significantly more often in the patient group with genotype B than in the patient group with genotype C (P < 0.0001). Baseline HBeAg-positivity was significantly less common in patients with genotype B than in those with genotype C (34.5% versus 66.0%; P ‫ס‬ 0.0002). A baseline ALT abnormality was also significantly less common in patients with genotype B than in those with genotype C (22.4% versus 84.0%; P < 0.0001).
RESULTS
Genotype distribution of HBV.
Age-and sex-specific HBeAg prevalences by HBV genotype. Table 2 shows the age-and sex-specific prevalences of HBeAg at entry of all the studied patients. The total HBeAg prevalence in patients with genotype B (34.5%) was significantly lower than that of patients with genotype C (66.0%) (P ‫ס‬ 0.0002). The sex-specific prevalence of HBeAg showed that male patients had a higher HBeAg positivity than female patients. There was a significant difference between sexes in those with genotype C (75.4% versus 53.5%, respectively; P ‫ס‬ 0.0374), but no significant difference in those with genotype B. The difference in HBeAg prevalence between genotypes B and C was statistically significant for male pa- Table 3 shows the disappearance of HBeAg during the observation period of patients who were HBeAg positive at entry by genotype. Of 86 patients who were HBeAg positive at entry, 43 (50.0%) converted from HbeAg positive to HbeAG negative by the end of the observation period. The annual rate of spontaneous HBeAg disappearance in patients with genotype B was much higher than that in patients with genotype C (8.38%/person-year versus 2.34%/person-year, respectively). Among 49 patients with genotype C treated with IFN, 25 (51.0%) showed disappearance of HBeAg during the observation period, 11 (22.4%) within one year after IFN treatment, and the remaining 14 (28.6%) more than one year after the treatment. All patients treated with IFN had genotype C and showed a higher annual rate of HBeAg disappearance than patients with genotype B who did not receive IFN treatment (12.56%/person-year versus 8.38%/person-year, respectively). Figure 2 shows the cumulative probability of HBeAg disappearance. The time to spontaneous HBeAg disappearance in patients with genotype B was significantly different from that in those with genotype C (P ‫ס‬ 0.0463, by log-rank test). The time to HBeAg disappearance in patients with genotype C treated with IFN was significantly different from that in patients not treated with IFN (P ‫ס‬ 0.0089, by the log rank test). However, the time of HBeAg disappearance in patients with genotype C treated with IFN was not significantly different from the spontaneous HBeAg disappearance in patients with genotype B who had not received IFN treatment.
Relationship between HBeAg status and ALT abnormality by HBV genotype. Table 4 shows the relationship between HBV markers (HBeAg and HBV DNA) and ALT abnormality. We classified all 158 patients into four groups according to HBeAg status during the observation period, as shown in the Materials and Methods. Group I patients with genotype C had a higher rate of ALT abnormalities (89.5%) than those with genotype B (60.0%); however, there was no statistically significant difference. Group IV patients with genotype C had significantly higher rate of ALT abnormalities (58.8%) than those with genotype B (19.2%) (P ‫ס‬ 0.0107). Interestingly, Group III patients with genotype C had a remarkably high rate of ALT abnormalities in spite of converting from HbeAg positive to negative after IFN treatment. These findings suggest that patients with genotype C frequently had ALT abnormalities regardless of whether their HBeAg status was positive or negative. Among all groups, all patients with ALT abnormalities were had HBV DNA in their serum when tested by the TMA-HPA.
Difference between patients in Okinawa and Fukuoka by HBV genotype. Among the Okinawa patients, those with genotype B had a lower rate of baseline HBeAg positivity (20 of 53, 43.4%) than patients with genotype C (6 of 8, 75.0%), and also had a higher rate of HBeAg disappearance during the observation period (15 of 20, 75.0%) than those with genotype C (2 of 6, 33.3%). Moreover, patients with genotype B had ALT abnormalities significantly less often (15 of 53, 28.3%) than patients with genotype C (6 of 8, 75.0%) (P ‫ס‬ 0.0160). Among the Fukuoka patients, those with genotype B had characteristics similar to those in Okinawa when compared with the Fukuoka patients with genotype C: baseline HbeAg positivity (none of 5, 0% versus 60 of 92, 65.2%, respectively), rate of HBeAg disappearance (none because all patients were HBeAg negative versus 26 of 60, 43.3%, respectively), and the rate of ALT abnormalities (1 of 5, 20.0% versus 66 of 92, 71.7%, respectively). These findings showed * HBeAg ‫ס‬ hepatitis B e antigen; HBV ‫ס‬ hepatitis B virus; IFN ‫ס‬ interferon. The X and Y group patients were followed over 18.2 ± 3.3 years and 7.5 ± 4.3 years (mean ± SD) from the start of the observation period, respectively. The Z group patients were followed over 4.6 ± 2.9 years (mean ± SD) from the start of IFN treatment.
† Estimated by the person-year method.
FIGURE 2. Cumulative probability of hepatitis B virus e antigen (HBeAg) disappearance, by hepatitis B virus (HBV) genotypes B and C, and interferon (IFN) treatment status in Japanese patients with chronic HBV infection. There was a significant difference in HBeAg disappearance between patients with genotype B and those with genotype C who did not receive IFN (genotype B ‫ס‬ 20 patients, genotype C ‫ס‬ 17 patients; P ‫ס‬ 0.0463, by log rank test). There was a significant difference in HBeAg disappearance between patients with genotype C with and without IFN treatment (with IFN ‫ס‬ 49 patients, without IFN ‫ס‬ 17 patients; P ‫ס‬ 0.0089, by the log rank test). similar differences by HBV genotype between patients in Okinawa and Fukuoka.
DISCUSSION
We investigated the prevalence of HBV genotype by use of an ELISA and retrospectively determined the effect of genotypic differences on the clinical course of Japanese patients with chronic HBV infection.
The HBV genotypes among HBV-infected patients have a characteristic geographic distribution. [12] [13] [14] [15] [16] Genotypes B and C are commonly observed in Southeast Asia and the Far East. 15, 20 In the present study, genotypes B and C were the only serotypes found among Japanese patients with chronic HBV infection in Fukuoka and Okinawa, Japan. An investigation of 514 Japanese blood donors from various geographic areas of Japan showed the predominant genotypes to be genotypes B and C, and infrequently found genotypes A, D, and F. 18 Japan is apparently at a geographic boundary of genotypes B and C, forming a south to north gradient in which genotype C is more frequent in the south (Kyushu) and genotype B is more frequent in the north (Tohoku). Interestingly, however, genotype B is more frequent in Okinawa, the southernmost area of Japan. 18 The present study confirmed that genotype C was predominant in Fukuoka and that genotype B was predominant in Okinawa.
The HBV genotypes B and C in the present study were associated with HBsAg subtypes adw and adr, respectively, as previously reported. 18, 20 However, HBV genotypes do not necessarily parallel HBsAg subtypes, which are specified by only two point mutations: codon 122 and codon 160 of the HBV S gene. 12 Moreover, it is difficult to relate the different clinical courses of HBV infection classified by HBsAg subtype because there are several compound HBsAg subtypes, such as adyr, adwr, or undetermined subtypes. 17, 18 Since 1994, it has been possible to determine HBV genotypic differences reflected in the genome sequence by the polymerase chain reaction. 13 Restriction fragment length polymorphism of the S gene sequence testing was later introduced for HBV genotyping. 21 Because these HBV genotyping methods depend on the nucleotide sequence, and are thus not suitable for largescale surveys, we used a serologic ELISA with monoclonal antibodies against genotypic epitopes in the pre-S gene product to detect HBV genotypes for its wider application, ease, and low cost. 18 In fact, compound HBsAg subtypes and undetermined subtypes could be classified by HBV genotype by the assay used in the present study. The HBV genotypes detected by ELISA would be useful for analysis of patients with HBV infection.
Most clinical trials of the natural course and treatment of chronic hepatitis B were done over relatively short periods of time. In our long-term study, the HBeAg positivity rate at the start of the observation period was significantly lower in Japanese patients with genotype B, most often found in the Yaeyama District of Okinawa than in those with genotype C, most often found in Fukuoka. The annual rate of spontaneous HBeAg disappearance was also higher in the patients with genotype B than in those with genotype C. We previously reported that the HBeAg prevalence was significantly lower in Okinawa than in Fukuoka, that HBeAg-positive carriers seroconverted to anti-HBe at a younger age in Okinawa than in Kyushu, and that these differences were related to HBsAg subtype. 10, 17 These results confirmed a pathogenic difference between the B and C genotypes. [22] [23] [24] A study of east Asian patients other than Japanese found genotype B compared with be associated with a faster transition through the immunoactive stage and a faster seroconversion from HBeAg to anti-HBe than genotype C, while genotype C was associated with more pronounced liver inflammation. 25 These findings suggest the possibility that HBV genotypic variability may be related to HBeAg secretion into the serum and to the pathogenicity of HBV-induced liver damage.
Before the introduction of HBV genotyping assay, it was well documented that HBeAg was more prevalent in males than females, 26 and that female patients with chronic HBV infection clear HBeAg more rapidly than male patients. 10 We found a significant difference between the sexes in HBeAg prevalence among patients with genotype C, but not among those with genotype B. These findings suggest that an HBV genotypic difference is of more influence than a sex-related difference in HBV pathogenicity.
In Japan, highly socialized medicine is practiced. Everyone is covered by some form of health insurance. People can frequently consult physicians, who can perform extensive inves- tigation regardless of cost. As was described in the Materials and Methods, treatment with IFN was done only for those who positive for HBeAg under the medical insurance system rule. This explains why only genotype C patients were treated with IFN in the present study because they showed a tendency to have continued HBeAg positivity. The annual HBeAg disappearance rate in patients with genotype C who received IFN treatment was 12.56% in the present study. The rate of spontaneous HBeAg disappearance in patients with chronic HBV infection has been reported to be significantly increased by IFN treatment. 27, 28 Taiwanese researchers investigated the efficacy of IFN treatment of patients with chronic hepatitis B in an area geographically close to the Okinawa districts we studied and reported a significant difference in the response (normalization of ALT levels and disappearance of HBeAg and HBV DNA) between HBV genotypes B (41%) and C (15%). 23 Patients with genotype B tended to have a higher HBeAg disappearance rate, both by the natural course and when induced by IFN than those with genotype C. We assumed that the efficacy for HBeAg disappearance by treatment with IFN also depended on HBV genotype, although there were no patients with genotype B treated with IFN in the present study.
The disappearance of HBeAg with or without seroconversion of antibody to HBeAg does not always imply cessation of viral replication or disease remission because certain viral mutations do not produce HBeAg but remain replicative. 29, 30 Many patients who showed a disappearance of HBeAg were found to have a G to A mutation at nucleotide 1896 in the precore region that converts codon 28 for tryptophan to a stop codon, stopping the production of HBeAg, 29 or an A to T mutation at nucleotide 1762 and G to A mutation at nucleotide 1764 in the core promoter region, which reduce synthesis of HBeAg by suppressing the transcription of precore mRNA. 31 Chronic active hepatitis B without HBeAg has been reported in the Middle East, Asia, Japan, and Hong Kong, 31 ,32 but is extremely rare in the United States. 33 Recently, it was reported that the viral precore promoter and/or precore region mutations might allow the persistence of viral replication after HBeAg disappearance, depending on HBV genotype. 22, 25 However, no large-scale population studies of the difference in HBV viral replication and liver damage after HBeAg disappearance between patients with and without treatment with IFN have been done, although the persistence of HBV DNA detected in the serum of patients with HBeAg disappearance after antiviral therapy was demonstrated in a small population study. 34 In the present study, there was an HBV genotypic significant difference in the ALT abnormality rate of patients HBeAg negative at the start and end of the observation period (genotype B ‫ס‬ 19.2% versus genotype C ‫ס‬ 58.8%). Also, the majority (72.0%) of patients with genotype C who converted from HBeAg positive to HBeAg negative after treatment with IFN had ALT abnormalities and were HBV DNA positive, although HBeAg disappearance was associated with sustained remission of viral replication and liver disease. 35 These findings suggest that HBeAg disappearance signifies a decrease in viral replication and liver damage in most patients with genotype B, but not in the majority of patients with genotype C.
In conclusion, we confirmed that HBV genotypes B and C are the most prevalent in Japan. Overall, HBV genotype C may show less HBeAg disappearance and be associated with a higher ALT abnormality rate and HBV DNA positivity after HBeAg disappearance than genotype B, suggesting that genotype C patients have more serious liver deterioration because of the delay of HBeAg disappearance and the presence of HBV replication after HBeAg disappearance. Since it was possible that fewer numbers of true asymptomatic genotype C carriers with persistently normal ALT levels might be included in the present study, compared with genotype B carriers, we cannot completely exclude the absence of a direct link with liver damage. More population studies of HBV genotypes are needed to determine the true prevalence of subgroups of chronic hepatitis B in patients who experienced reactivation or had liver damage after HBeAg disappearance and who might be at greater risk of disease progression to cirrhosis and hepatocellular carcinoma.
